Nobias Therapeutics

General Information

Company Name

Nobias Therapeutics

Founded Year

2020

Location (Offices)

Philadelphia, United States +1

Founders / Decision Makers

Number of Employees

Industries

Health Care, Health and Wellness

Funding Stage

Series A

Social Media

Nobias Therapeutics - Company Profile

Nobias Therapeutics is an AI-first therapeutics company founded in 2020, with a focus on the health care sector. The company is currently engaged in a phase 2 clinical trial aimed at addressing symptoms of anxiety, inattention, and autism in children with 22q11 deletion syndrome. Nobias has recently secured a significant $3.75M Series A investment on 24 July 2020, with Domain Associates as the lead investor. This funding is poised to support the company's mission of leveraging AI to revolutionize therapeutic interventions. With its innovative approach and strong backing, Nobias Therapeutics is shaping up to be a significant player in the biotech space.

Taxonomy: AI-first, therapeutics, clinical trial, anxiety treatment, attention treatment, autism treatment, pediatric therapies, 22q11 deletion syndrome, phase 2, drug development, neurobehavioral disorders